Incremental Diagnostic Value of Tau-PET With [18F]RO948 vs Amyloid-PET in Patients With Cognitive Impairment
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age50-85
SponsorUniversity Hospital, Geneva
About this trial
The objective of the study is to investigate the clinical validity of tau-PET with \[18F\]RO948 vs. amyloid-PET in patients with Mild Cognitive Impairment (MCI) or mild dementia
Eligibility criteria
Qualifiers
Written Inform Consent to participating.
50 to 85 years of age
a diagnosis of Mild Cognitive Impairment (MCI=at least one pathological neuropsychological test but no functional impairment based on the Amsterdam IADL score) or mild dementia (both cognitive and functional impairments)
availability of MRI within 6 months before screening
Disqualifiers
The presence of psychiatric disorders, extensive white matter lesions or other stigmata of vascular dementia.
Visual and auditory acuity inadequate for neuropsychological testing.
Enrolment in previous clinical trials for AD potentially affecting amyloid and/or tau brain load
Enrolment in other trials or studies not compatible with [18F]RO948 Imaging study.
Trial design
Treatments tested in this trial
- PET/CT with RO958 (experimental)
Treatment groups
120 Participants
are divided into 2 treatment groupsSponsors and collaborators
University Hospital, Geneva
Lead sponsor
Centre Hospitalier Universitaire Vaudois
Collaborator
Source ClinicalTrials.gov